Renal Cancer - Results from #460

A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma. February 29, 2024

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. February 28, 2024

The Impact of a Multidisciplinary Tumor Board (MTB) on Treatment Decision Making for Patients With Renal Cell Carcinoma (RCC): 5-Year Data Analysis. February 28, 2024

Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial. February 27, 2024

Magnetic resonance imaging-guided renal biopsy shows high safety and diagnostic yield: a tertiary cancer center experience. February 27, 2024

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma. February 26, 2024

Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. February 26, 2024

CT-derived radiomics predict the growth rate of renal tumours in von Hippel-Lindau syndrome. February 23, 2024

Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study. February 23, 2024

Percutaneous Microwave Ablation vs Cryoablation for Small Renal Masses (≤4cm): 12-Year Experience at a Single Center. February 22, 2024

External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. February 22, 2024

Scoring system for prediction of overall survival in patients with renal cell carcinoma T3aN0M0. February 21, 2024

Development and validation of a nomogram for predicting the impact of tumor size on cancer-specific survival of locally advanced renal cell carcinoma: a SEER-based study. February 21, 2024

PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer. February 20, 2024

A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma. February 20, 2024

Robotic transperitoneal versus retroperitoneal approach for anterior renal mass nephron-sparing surgery. February 19, 2024

Prognostic significance of pT3a staging subclassifications in renal cell carcinoma: Not all pT3a are equal. February 19, 2024

Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma. February 16, 2024

Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer. February 16, 2024

Disruption of Autophagic Flux and Treatment with the PDPK1 Inhibitor GSK2334470 Synergistically Inhibit Renal Cell Carcinoma Pathogenesis. February 16, 2024

Page 24 of 455